Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study.

Georgiadou P, Iliodromitis EK, Kolokathis F, Varounis C, Gizas V, Mavroidis M, Capetanaki Y, Boudoulas H, Kremastinos DT.

Eur J Clin Invest. 2010 Apr;40(4):288-93. doi: 10.1111/j.1365-2362.2010.02257.x.

PMID:
20192976
2.

Prognostic significance of plasma osteopontin levels in patients with chronic stable angina.

Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, Geroldi D.

Eur Heart J. 2006 Apr;27(7):802-7. Epub 2006 Jan 18.

PMID:
16421174
3.

Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention.

Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K, Nakamura H, Ohsuzu F.

Circ J. 2009 Jan;73(1):152-7. Epub 2008 Nov 21.

4.

Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis.

Abdel-Azeez HA, Al-Zaky M.

J Clin Lab Anal. 2010;24(3):201-6. doi: 10.1002/jcla.20378.

PMID:
20486203
5.

Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris.

Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC.

Eur Heart J. 2005 Mar;26(5):457-63. Epub 2005 Jan 31.

PMID:
15684278
6.

Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.

Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW.

Eur J Clin Invest. 2005 Sep;35(9):537-45.

PMID:
16128859
7.

Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease.

Georgiadou P, Iliodromitis EK, Varounis C, Mavroidis M, Kolokathis F, Andreadou I, Psarras S, Capetanaki Y, Boudoulas H, Kremastinos DT.

Expert Opin Ther Targets. 2008 Aug;12(8):917-20. doi: 10.1517/14728222.12.8.917 .

PMID:
18620515
8.

Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study.

Morange PE, Blankenberg S, Alessi MC, Bickel C, Rupprecht HJ, Schnabel R, Lubos E, Münzel T, Peetz D, Nicaud V, Juhan-Vague I, Tiret L; Atherogene Investigators.

J Thromb Haemost. 2007 Mar;5(3):475-82. Epub 2007 Jan 4.

9.

B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study.

Schnabel R, Lubos E, Rupprecht HJ, Espinola-Klein C, Bickel C, Lackner KJ, Cambien F, Tiret L, Münzel T, Blankenberg S.

J Am Coll Cardiol. 2006 Feb 7;47(3):552-8. Epub 2006 Jan 18.

10.

Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease.

Lorenzen J, Krämer R, Kliem V, Bode-Boeger SM, Veldink H, Haller H, Fliser D, Kielstein JT.

Eur J Clin Invest. 2010 Apr;40(4):294-300. doi: 10.1111/j.1365-2362.2010.02271.x.

PMID:
20486990
11.

Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma.

Xie H, Song J, Du R, Liu K, Wang J, Tang H, Bai F, Liang J, Lin T, Liu J, Fan D.

Dig Liver Dis. 2007 Feb;39(2):167-72. Epub 2006 Dec 11.

PMID:
17161983
12.

Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators.

Lamas GA, Flaker GC, Mitchell G, Smith SC Jr, Gersh BJ, Wun CC, Moyé L, Rouleau JL, Rutherford JD, Pfeffer MA, et al.

Circulation. 1995 Sep 1;92(5):1101-9.

PMID:
7648653
13.

Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy.

Snitcovsky I, Leitão GM, Pasini FS, Brunialti KC, Mangone FR, Maistro S, de Castro G Jr, Villar RC, Federico MH.

Arch Otolaryngol Head Neck Surg. 2009 Aug;135(8):807-11. doi: 10.1001/archoto.2009.103.

PMID:
19687403
14.

Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study.

Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, Espinola-Klein C, Lackner KJ, Tiret L, Münzel T, Blankenberg S; AtheroGene Investigators.

Eur Heart J. 2006 Dec;27(24):2962-8. Epub 2006 Nov 28.

PMID:
17132649
15.

Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris.

Cosin-Sales J, Kaski JC, Christiansen M, Kaminski P, Oxvig C, Overgaard MT, Cole D, Holt DW.

Eur Heart J. 2005 Oct;26(20):2093-8. Epub 2005 Jul 29.

PMID:
16055491
16.

Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support.

Schipper ME, Scheenstra MR, van Kuik J, van Wichen DF, van der Weide P, Dullens HF, Lahpor J, de Jonge N, De Weger RA.

J Heart Lung Transplant. 2011 Jul;30(7):805-10. doi: 10.1016/j.healun.2011.03.015. Epub 2011 May 4.

PMID:
21531579
17.

Plasma osteopontin is an independent prognostic marker for head and neck cancers.

Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, Giaccia AJ, Le QT.

J Clin Oncol. 2006 Nov 20;24(33):5291-7.

PMID:
17114663
18.

Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina.

Elesber AA, Conover CA, Denktas AE, Lennon RJ, Holmes DR Jr, Overgaard MT, Christiansen M, Oxvig C, Lerman LO, Lerman A.

Eur Heart J. 2006 Jul;27(14):1678-84. Epub 2006 May 22.

PMID:
16717071
19.

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators.

Circulation. 2007 Mar 27;115(12):1528-36. Epub 2007 Mar 19.

PMID:
17372173
20.

[The prognostic significance of preoperative plasma level of osteopontin in combination with intercellular adhesion molecule-1 for patients with hepatocellular carcinoma].

Zhang H, Ren N, Ye QH, Sun HC, Wang L, Liu YK, Tang ZY, Qin LX.

Zhonghua Wai Ke Za Zhi. 2005 Aug 1;43(15):985-8. Chinese.

PMID:
16194354

Supplemental Content

Support Center